Company newsForm 8-K

AbCellera Biologics ABCL

AbCellera Biologics appoints Lynn Seely to its board of directors

Seely is president and CEO of Lyell Immunopharma Inc. and was previously CEO of Myovant Sciences Inc.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

AbCellera Biologics said its board appointed Lynn Seely, M.D., as a Class III director on June 30, 2026. The board determined she is independent under NASDAQ rules and the company's governance guidelines, and she has no committee seat.

The company said she will serve until the 2029 annual meeting of shareholders.

Key facts

Position
Class III director
Appointed
June 30, 2026
Term ends
2029 annual meeting of shareholders
Committee seats
None

All ABCL news

Source: Form 8-K filed July 6, 2026. The company's release as filed with the SEC.

Written by GetSignal with AI from the company's SEC filing. How we make news

Not investment advice.

More company news

AbCellera Biologics first, then the newest

All company news